SCHEMBL2153408

SCHEMBL2153408

CC(=O)NC(c1ccccc1)c1cc([N+](=O)[O-])c2cccnc2c1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 1.00
KMT2A Q03164 12/20 1.00
HTT P42858 11/20 1.00
KDM4E B2RXH2 11/20 1.00
MEN1 O00255 10/20 1.00
L3MBTL1 Q9Y468 10/20 1.00
SMN1; SMN2 Q16637 10/20 1.00
LMNA P02545 9/20 1.00
ALDH1A1 P00352 2/20 1.00
PKM P14618 1/20 1.00
TDP1 Q9NUW8 9/20 0.85
RAB9A P51151 5/20 0.85
NPC1 O15118 4/20 0.85
CCR6 P51684 2/20 0.85
ALOX12 P18054 7/20 0.83
POLB P06746 2/20 0.83
GAA P10253 2/20 0.74
ADAMTS5 Q9UNA0 2/20 0.72
HSP90AA1 P07900 2/20 0.72
RECQL P46063 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL608716 0.92 KMT2A (1.00) MAPTKMT2AHTTKDM4EMEN1
SCHEMBL1542189 0.91 KMT2A (0.83) MAPTKMT2AHTTKDM4EMEN1
SCHEMBL2153850 0.91 MAPT (1.00) MAPTKMT2AHTTKDM4EMEN1
SCHEMBL30868633 0.89 KMT2A (0.80) MAPTKMT2AHTTKDM4EMEN1
SCHEMBL1542152 0.89 KMT2A (0.80) MAPTKMT2AHTTKDM4EMEN1
SCHEMBL12839880 0.87 ALOX12 (0.81) MAPTKMT2AHTTKDM4EMEN1
SCHEMBL2153339 0.85 KDM4E (0.74) MAPTKMT2AHTTKDM4EMEN1
SCHEMBL608048 0.85 KDM4E (1.00) MAPTKMT2AHTTKDM4EMEN1
SCHEMBL1814003 0.84 ADAMTS5 (1.00) MAPTKMT2AHTTKDM4EMEN1
SCHEMBL2153908 0.84 HTT (0.72) MAPTKMT2AHTTKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 US disclosed
US-20120295890-A1 GLYCOSAMINOGLYCAN INHIBITORS Zacharon Pharmaceutical, Inc. (US) 2012-11-22 US disclosed
WO-2011082175-A2 GLYCOSAMINOGLYCAN INHIBITORS ZACHARON PHARMACEUTICALS, INC. (US) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295890-A1 GLYCOSAMINOGLYCAN INHIBITORS CSGALNACT1, FUT5, ST3GAL3 MAPT 4328/4885KMT2A 4294/4885HTT 2106/4885
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression TERT, TERF2, RNGTT MAPT 2505/4885KMT2A 280/4885HTT 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.